FORUM MARKETS Inc

The registrant was unable to file its Annual Report on Form 10-K for the year ended December 31, 2025 (the “ Report ”), by the prescribed date of March 31, 2026, without unreasonable effort or expense, because the registrant needed additional time to complete certain disclosures and analyses included in the Report. In accordance with Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended, the registrant plans to file the Report on April 1, 2026, but in any case on or prior to the fifteenth (15th) calendar day following the prescribed due date

Life Sciences Corp. (the “ Registrant ”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “ Quarterly Report ”) by the prescribed due date for the reasons described below. On August 9, 2023, the Registrant priced a public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65 (the “ Offering ”). The closing of the Offering is expected to occur on or about August 14, 2023, subject to the satisfaction of customary closing conditions. The Registrant has needed to dedicate significant resources to the Offering, including its management’s attention, and expects to continue to devote significant resources to the closing of the Offering. As a result of the foregoing, the Registrant cannot, without unreasonable effort or expense, file the Quarterly Report by the original due date. The Registrant plans to file its Quarterly Report with the Securities and Exchange Commission (“ SEC ”) as soon as practicable and within the five calendar day period provided by Rule 12b-25 for delayed filings

As previously reported, on November 6, 2020 (the “ Closing Date ”), the Registrant consummated the previously announced business combination (the “ Business Combination ”) following a special meeting of stockholders held on November 5, 2020, where the stockholders of 180 Life Sciences Corp., formerly KBL Merger Corp. IV (the “ Registrant ” or, prior to the closing of the Business Combination, sometimes referred to herein as “ KBL ”) considered and approved, among other matters, a proposal to adopt that certain Business Combination Agreement (as amended, the “ Business Combination Agreement ”), dated as of July 25, 2019, entered into by and among the Registrant, KBL Merger Sub, Inc. (“ Merger Sub ”), 180 Life Corp. formerly 180 Life Sciences Corp. (“ 180 ”), Katexco Pharmaceuticals Corp. (“ Katexco ”), CannBioRex Pharmaceuticals Corp. (“ CBR Pharma ”), 180 Therapeutics L.P. (“ 180 LP ” and together with Katexco and CBR Pharma, the “ 180 Subsidiaries ” and, together with 180, the “ 180 Parties ”), and Lawrence Pemble, in his capacity as representative of the stockholders of the 180 Parties (the “ Stockholder Representative ”). Pursuant to the Business Combination Agreement, among other things, Merger Sub merged with and into 180, with 180 continuing as the surviving entity and a wholly-owned subsidiary of the Registrant (the “ Merger ”). The Merger became effective on November 6, 2020 (such time, the “ Effective Time ”, and the closing of the Merger being referred to herein as the “ Closing ”). In connection with, and prior to, the Closing, 180 filed a Certificate of Amendment of its Certificate of Incorporation in Delaware to change its name to 180 Life Corp. and KBL Merger Corp. IV changed its name to 180 Life Sciences Corp

As previously reported, on November 6, 2020 (the “ Closing Date ”), the Registrant consummated the previously announced business combination (the “ Business Combination ”) following a special meeting of stockholders held on November 5, 2020, where the stockholders of 180 Life Sciences Corp., formerly KBL Merger Corp. IV (the “ Registrant ” or, prior to the closing of the Business Combination, sometimes referred to herein as “ KBL ”) considered and approved, among other matters, a proposal to adopt that certain Business Combination Agreement (as amended, the “ Business Combination Agreement ”), dated as of July 25, 2019, entered into by and among the Registrant, KBL Merger Sub, Inc. (“ Merger Sub ”), 180 Life Corp. formerly 180 Life Sciences Corp. (“ 180 ”), Katexco Pharmaceuticals Corp. (“ Katexco ”), CannBioRex Pharmaceuticals Corp. (“ CBR Pharma ”), 180 Therapeutics L.P. (“ 180 LP ” and together with Katexco and CBR Pharma, the “ 180 Subsidiaries ” and, together with 180, the “ 180 Parties ”), and Lawrence Pemble, in his capacity as representative of the stockholders of the 180 Parties (the “ Stockholder Representative ”). Pursuant to the Business Combination Agreement, among other things, Merger Sub merged with and into 180, with 180 continuing as the surviving entity and a wholly-owned subsidiary of the Registrant (the “ Merger ”). The Merger became effective on November 6, 2020 (such time, the “ Effective Time ”, and the closing of the Merger being referred to herein as the “ Closing ”). In connection with, and prior to, the Closing, 180 filed a Certificate of Amendment of its Certificate of Incorporation in Delaware to change its name to 180 Life Corp. and KBL Merger Corp. IV changed its name to 180 Life Sciences Corp